Julie Parsons, MD

July 20, 2021

John Brandsema, MD, and Julie Parsons, MD, review the evolution of combination therapy in clinical practice for the management of SMA.

July 17, 2021

John Brandsema, MD, comments on the importance of patient compliance to therapy to manage spinal muscular atrophy.

July 17, 2021

Experts in pediatric neurology share insights on the role of small molecule treatment for SMA through the recent FDA approval of risdiplam and discuss factors to consider when tailoring therapy for individual patients.

July 10, 2021

John Brandsema, MD, leads the discussion on the concept of gene transfer for the management of SMA and the recent approval of onasemnogene abeparvovec-xioi.

July 10, 2021

Experts in pediatric neurology provide insight on the efficacy of nusinersen and treatment response in patients with SMA.

June 29, 2021

John Brandsema, MD, and Julie Parsons, MD, discuss the approval of nusinersen for the treatment of spinal muscular atrophy and their personal experiences regarding drug safety and administration in patients.

June 29, 2021

Expert pediatric neurologists review the importance of early recognition and referral to neurologists for the diagnosis of spinal muscular atrophy and when it’s appropriate to approach treatment.

June 22, 2021

Julie Parsons, MD, comments on the role of primary care providers and gene testing for the early diagnosis of spinal muscular atrophy.

June 22, 2021

Identifying spinal muscular atrophy through early diagnosis using prenatal and newborn screenings is discussed.

June 15, 2021

Julie Parsons, MD, discusses the importance of a multidisciplinary team approach to managing SMA in clinical practice.